Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.36 |
| ▸ | ORAI2 | Q96SN7 | 2/20 | 0.36 |
| ▸ | ORAI3 | Q9BRQ5 | 2/20 | 0.36 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9777193 | 0.80 | ALDH1A1 (0.36) | ALDH1A1TSHRORAI1ORAI2ORAI3 | |
| SCHEMBL7078619 | 0.76 | SMN1; SMN2 (0.36) | ALDH1A1CYP2C19KDM4EHPGDCYP1A2 | |
| SCHEMBL15690945 | 0.74 | ALDH1A1 (0.37) | ALDH1A1KDM4EHPGDCYP1A2CYP3A4 | |
| SCHEMBL1159537 | 0.69 | MAPT (0.41) | ALDH1A1TSHRKDM4EKMT2AHTT | |
| Allylamine SCHEMBL6678252 | 0.68 | ALDH1A1 (0.43) | ALDH1A1TSHRORAI1ORAI2ORAI3 | |
| SCHEMBL1158664 | 0.67 | GABRA1 (0.41) | ALDH1A1TSHRKDM4ECYP1A2GABRA1 | |
| SCHEMBL2143304 | 0.65 | CYP3A4 (0.38) | ALDH1A1TSHRORAI1ORAI2ORAI3 | |
| SCHEMBL1474212 | 0.65 | ORAI1 (0.41) | ALDH1A1TSHRORAI1ORAI2ORAI3 | |
| SCHEMBL14798475 | 0.65 | TRPV6 (0.48) | ALDH1A1TSHRORAI1ORAI2ORAI3 | |
| SCHEMBL333263 | 0.65 | PCSK9 (0.43) | ALDH1A1TSHRORAI1ORAI2ORAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7521455-B2 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ALDH1A1 1717/4885TSHR 227/4885ORAI1 2304/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | ALDH1A1 1717/4885TSHR 227/4885ORAI1 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.